Halozyme Therapeutics Inc (HALO)

[aniustudent]

Addressing your comment that 'the longer survival of a few patients won't move the ($HALO) stock much', I disagree. A longer Overall survival (OS) is, sadly, what this study (after safety) is aiming for - not remission. There are, basically, no other options when it comes to pancreatic cancer for patients, offering a potential OS like that seen in the Phase lb. Furthermore, if there is even more of a correlation between the longest survivors and the % of hyaluronan (HA) in their tumors, it would excite the FDA, which would indeed excite the market. Yes, this doesn't mean instant HALO revenue. Yet, it does mean potential HALO revenue (years from now), and really -when it comes to biotechs- that's what the market adores.